澳股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

NEURIZON THERAPEUTICS LTD

0.091

+0.0022.25%

成交量：3.24万

成交额：2,947

市值：7,136.36万

市盈率：-5.17

高：0.091

开：0.090

低：0.090

收：0.089

52周最高：0.150

52周最低：0.053

股本：7.84亿

流通股本：3.51亿

量比：0.34

换手率：0.01%

股息：- -

股息率：- -

每股收益(TTM):-0.018

每股收益(LYR):-0.018

净资产收益率：-137.94%

总资产收益率：-45.31%

市净率：5.61

市盈率(LYR):-5.17

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

Neurizon Therapeutics：FDA C类会议确认正在进行的Healey ALS平台试验或可作为注册性试验

Neurizon Therapeutics任命Chris Bremer为新任首席执行官

海利ALS平台试验方案I完成入组 - Nuz-001顶线结果加速至2027年第二季度

BUZZ-澳大利亚Neurizon Therapeutics公司因与美国企业达成交易股价大涨

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/NUZ.AU"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NUZ.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","market":"AU","secType":"STK","nameCN":"NEURIZON THERAPEUTICS LTD","latestPrice":0.091,"timestamp":1791847399703,"preClose":0.089,"halted":0,"volume":32398,"delay":0,"changeRate":0.02247191011235957,"nameEN":"NEURIZON THERAPEUTICS LTD","floatShares":351374969,"shares":784215600,"eps":-0.0176,"marketStatus":"交易中","change":0.002,"latestTime":"10-13 11:02:54 AEDT","open":0.09,"high":0.091,"low":0.09,"amount":2947,"amplitude":0.011236,"askPrice":0.092,"askSize":5450,"bidPrice":0.088,"bidSize":50000,"shortable":3,"etf":0,"ttmEps":-0.0176,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1791867600000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.089,"openAndCloseTimeList":[[1791846000000,1791867600000]],"volumeRatio":0.344922,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"NUZ.AU","preClose":0.092,"auctionPrice":0.092,"auctionVolume":834,"auction":3,"marketStatus":"盘后竞价","timestamp":1791781200851}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","floatShares":351374969,"roa":"-45.31%","roe":"-137.94%","lyrEps":-0.0176,"volumeRatio":0.344922,"shares":784215600,"dividePrice":0,"high":0.091,"amplitude":0.011236,"preClose":0.089,"low":0.09,"week52Low":0.053,"pbRate":"5.61","psRate":"4.06","week52High":0.15,"institutionHeld":0,"latestPrice":0.091,"committee":0.803427,"eps":-0.0176,"divideRate":0,"volume":32398,"delay":0,"ttmEps":-0.0176,"open":0.09,"prevYearClose":0.085,"prevWeekClose":0.092,"prevMonthClose":0.078,"prevQuarterClose":0.078,"fiveDayClose":0.087,"twentyDayClose":0.075,"sixtyDayClose":0.064,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NUZ.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NUZ.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NUZ.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1111090022","title":"Neurizon Therapeutics：FDA C类会议确认正在进行的Healey ALS平台试验或可作为注册性试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1111090022","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111090022?lang=zh_cn&edition=fundamental","pubTime":"2026-10-06 06:59","pubTimestamp":1791241148,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics 宣布，美国食品药品监督管理局（FDA）C类会议已确认，正在开展的 Healey ALS 平台试验具备潜在注册性研究的资格。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173015776","title":"Neurizon Therapeutics任命Chris Bremer为新任首席执行官","url":"https://stock-news.laohu8.com/highlight/detail?id=1173015776","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173015776?lang=zh_cn&edition=fundamental","pubTime":"2026-09-07 09:42","pubTimestamp":1788745358,"startTime":"0","endTime":"0","summary":"9月7日（路透社）——Neurizon Therapeutics Ltd宣布重大人事变动。该公司正式任命Chris Bremer为首席执行官，此项任命自2026年10月1日起正式生效。这一战略性人事调整标志着公司进入新的发展阶段。\n值得关注的是，Neurizon Therapeutics Limited作为一家在澳大利亚交易所上市的制药企业（股票代码：NUZ.AX），此次高层管理团队的更迭备受市场瞩目。新任CEO的加入将为公司带来怎样的战略变革与发展机遇，业界正拭目以待。\n关于Neurizon Therapeutics的更多后续动态，市场将持续关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164737610","title":"海利ALS平台试验方案I完成入组 - Nuz-001顶线结果加速至2027年第二季度","url":"https://stock-news.laohu8.com/highlight/detail?id=1164737610","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164737610?lang=zh_cn&edition=fundamental","pubTime":"2026-07-17 11:50","pubTimestamp":1784260213,"startTime":"0","endTime":"0","summary":"海利肌萎缩侧索硬化症（ALS）平台试验方案I的患者招募工作已全部完成。这一关键里程碑的达成，使得针对试验药物Nuz-001的顶线结果数据发布时间得以提前。根据最新计划，该项重要数据的公布时间现已被加速至2027年第二季度。此举标志着针对这一难治性神经退行性疾病的新药研发进程取得了又一阶段性进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644479795","title":"BUZZ-澳大利亚Neurizon Therapeutics公司因与美国企业达成交易股价大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2644479795","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644479795?lang=zh_cn&edition=fundamental","pubTime":"2026-06-17 11:38","pubTimestamp":1781667529,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nL4T42P08R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","ELAN","NUZ.AU","BK4561","LU1941712264.USD","LU1941712348.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NUZ.AU\",params:#limit:6,delay:true,,,undefined,":[]}}